Six-month outcomes in postapproval HeartMate3 patients: A single-center US experience.

Aditya Bansal Faisal AkhtarSapna DesaiCruz Velasco-Gonzalez Anirudh BansalAngie TeagleAvni ShridharKaren WebreSheila OstrowDavid FaryPatrick Eugene Parrino

Published in: Journal of cardiac surgery (2022)

In this single-center study, the real-world 6-month survival in the postapproval group was comparable to the trial results. Further studies are needed to monitor long-term outcomes.

Keyphrases

type diabetes
glycemic control
end stage renal disease
insulin resistance
newly diagnosed
ejection fraction
chronic kidney disease
clinical trial
prognostic factors
peritoneal dialysis
study protocol
metabolic syndrome